Physician profile
James A Smith
NPI 1376630681
$2,507.53
in general payments reported to CMS, 2019-2025
19 companies · $664 in 2025
The $664 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,587 · 2020: $185 · 2021: $12.17 · 2022: $42.36 · 2023: $16.75 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $371 · Food and Beverage: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $371.32 |
| Food and Beverage | $309.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $663.68 | 2025 | |
| Janssen Pharmaceuticals, INC | $318.96 | 2019-2020 | |
| Lundbeck LLC | $246.54 | 2019-2020 | |
| Allergan, INC. | $200.80 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $197.54 | 2019-2020 | |
| Alkermes, INC. | $169.70 | 2019-2023 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $137.57 | 2019-2020 | |
| Shire North American Group INC | $108.04 | 2019 | |
| Neurocrine Biosciences, INC. | $84.77 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $72.79 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $71.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.30 | 2019 | |
| Tris Pharma INC | $51.08 | 2019 | |
| Neos Therapeutics, LP | $40.26 | 2019 | |
| Vanda Pharmaceuticals INC. | $25.78 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $18.90 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.96 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.25 | 2019 | |
| Alfasigma USA, INC. | $13.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.